Umbilical cord blood is currently used in the treatment of certain hematological and oncological diseases, such as leukemias, lymphomas, organ cancers, immune disorders or metabolism. In most of these diseases, hematopoiesis in the bone marrow fails. In bone marrow regeneration using hematopoietic stem cells, we speak of the so-called hematopoietic stem cell transplantation. Umbilical cord blood has already been used in more than 40,000 transplants worldwide.
Umbilical cord blood has huge potential in regenerative medicine, which deals with the regeneration of damaged tissues and organs.
Nearly 1 in 3 people may benefit over their lifetime from regenerative medicine, including therapies for neurological, cardiovascular, autoimmune, orthopedic diseases.
Regenerative medicine therapies may be the best hope for the patients with a lifetime of disability and impairment. Diseases such as stroke and spinal cord injury, myocardial infarction might possibly be treated with greater efficacy using umbilical cord blood therapy based approaches rather than current treatment options.
Who can benefit from umbilical cord blood treatment?
Treatment with own umbilical cord blood (autologous)
Transplantation of one’s own hematopoietic stem cells means that doctors use umbilical cord blood to treat a baby, to whom it has been taken at birth, at any time during the lifetime. Thus, the patient “donates own cells“. The great advantage is that the body and umbilical cord blood do not fight against each other, and therefore there are no complications after transplantation, which can happen when using cells from another person.
Own umbilical cord blood can be used in treatment in cases where own bone marrow or peripheral blood is used standardly. The need for treatment with own hematopoietic stem cells, as well as the determination of their source, is determined by the attending physician in cooperation with the transplant commission.
With age, there is an increasing frequency of the number of diseases which can be treated and globally more blood-forming stem cells are transported using the patient’s own umbilical cord, peripheral blood or bone marrow (60%) than from donor cell (40%).
Own cord blood is also being used in clinical trials for the treatment of cerebral palsy, autism, traumatic brain injury, spinal cord injury, acute burns and more.
The first results showed that when adequately dosed, cord blood may improve motor function in young children with spastic cerebral palsy.
Storing your child cord blood makes him/her anytime eligible for an autologous treatment.
Although own umbilical cord blood has many benefits, it is sometimes necessary to use umbilical cord blood from a sibling or foreign donor for treatment. In particular, these are cases where the disease is genetically determined and the umbilical cord blood itself would therefore not be an appropriate solution.
Using stem cell from cord blood for a sibling (allogeneic)
Umbilical cord blood can also be used to treat a sick sibling. When using cells from a donor, one of the important indicators of whether it will be possible to transplant umbilical cord blood, is the match of HLA markers. The most preferred donor is a matching sibling.
Compared to the administration of umbilical cord blood from a completely foreign donor, sibling transplants have better results and a lower risk of serious complications after transplantation. The probability that siblings HLA markers are matched in 100%, is 25%.
If the older sibling is ill and the mother is pregnant at the time, your doctor may recommend collecting cord blood for the needs of ill sibling. In this case, the parents do not pay for the collection, processing or storage of umbilical cord blood. More about the free collection for an ill sibling.
Treatment with cord blood from a donor (allogeneic)
A donor of cord blood can be an unrelated person. Finding a matching donor is the key to a successful allogeneic transplant. Matching cord blood can be searched in the register of donors of umbilical cord blood. A public registry, Slovak placental stem cell registry (Slovenský register placentárnych krvotvorných buniek), as a part of Cord Blood Center Group, is linked to an international database of public registries.
Umbilical cord blood from public registries is used especially for treating leukemia in children and adults or genetic disorders of blood formation and metabolism in child patients.
Allogeneic (donated) cord blood recently became being used in clinical trials for medicine regenerative applications. After the first promising results in the treatment of children with cerebral palsy, in order to extend this therapy, it was considered the possibility of using allogeneic cord blood in adults with ischemic stroke.
Very often there are misunderstandings over who can use cord blood in treatment. The short answer is it very much depends on the disease being treated. And it is finally the doctor’s decision.
Clinical studies in the world
Hundreds of clinical trials around the world verify the effectiveness of umbilical cord blood, umbilical cord tissue and placenta in various medical diagnoses.
1. Cerebral palsy, other acquired neurological disease in children, Ischemic Stroke, Traumatic brain injury and spinal cord injury, Autism, Acquired Hearing Loss in children, Alzheimer disease
2. Hypoplastic left heart syndrome
3. Crohn’s disease
4. Diabetes type I, II
5. Regeneration of bone tissue and cartilage
6. Rheumatoid arthritis
7. New approaches for transplantation of cord blood unit
8. Diabetic foot
9. Malignant and non-malignant diseases
Umbilical cord tissue
1. Systemic lupus erythematosus, Autism
2. Spinal Cord Injury
4. Hepatic failure and liver cirrhosis
5. Diabetes type I, II
6. Rheumatoid Arthritis, Ulcerative Colitis
7. GVHD for hematopoietic stem cell transplantation
8. Critical limb ischemia, extensive and severe burns
9. Multiple sclerosis, osteoarthritis
1. HIE (Hypoxia of the brain at birth)
2. Idiopathic pulmonary fibrosis
3. Ankylosing spondylitis
4. Support for hematopoietic stem cell transplantation
5. Crohn’s disease
6. Erectile dysfunction
7. Malignant and non-malignant hematological diseases